These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35569611)

  • 1. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.
    González-Juanatey JR; Cordero A; Castellano JM; Masana L; Dalmau R; Ruiz E; Sicras-Mainar A; Fuster V
    Int J Cardiol; 2022 Aug; 361():116-123. PubMed ID: 35569611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study.
    Cordero A; Dalmau González-Gallarza R; Masana L; Fuster V; Castellano JM; Ruiz Olivar JE; Zsolt I; Sicras-Mainar A; González Juanatey JR
    Clinicoecon Outcomes Res; 2023; 15():559-571. PubMed ID: 37489131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease.
    Dalmau R; Cordero A; Masana L; Ruiz E; Sicras-Mainar A; González-Juanatey JR
    Eur Heart J Open; 2024 Mar; 4(2):oeae027. PubMed ID: 38686352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg].
    González-Juanatey JR; Cordero A; Masana L; Dalmau R
    Arch Cardiol Mex; 2024 Jun; ():. PubMed ID: 38843861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.
    González-Domínguez A; Durán A; Hidalgo-Vega Á; Barrios V
    Rev Clin Esp (Barc); 2023; 223(7):414-422. PubMed ID: 37352973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
    González-Juanatey JR; Tamargo J; Torres F; Weisser B; Oudovenko N
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):51-58. PubMed ID: 31983653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.
    Aguiar C; Araujo F; Rubio-Mercade G; Carcedo D; Paz S; Castellano JM; Fuster V
    J Health Econ Outcomes Res; 2022; 9(2):134-146. PubMed ID: 36475278
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
    Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
    BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs.
    Portela-Romero M; Cinza-Sanjurjo S; Conde-Sabarís P; Rodríguez-Mañero M; Mazón-Ramos P; Rey-Aldana D; González-Juanateyc JR
    Rev Clin Esp (Barc); 2022 Mar; 222(3):131-137. PubMed ID: 34674985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
    Grigorian-Shamagian L; Coca A; Morais J; Perez-Martinez P;
    BMC Proc; 2023 Aug; 17(Suppl 8):20. PubMed ID: 37587509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.
    Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V;
    Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
    Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
    Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
    Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
    Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
    Tamargo J; Castellano JM; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S15-22. PubMed ID: 26747390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico: a
    Gómez-Álvarez E; Verdejo J; Ocampo S; Ruiz E; Martinez-Rios MA
    Future Cardiol; 2020 Jan; 16(1):53-60. PubMed ID: 31850802
    [No Abstract]   [Full Text] [Related]  

  • 19. Polypill Strategy in Secondary Cardiovascular Prevention.
    De la Rosa A; Arrington K; Desai R; Acharya PC
    Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.